{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:13:13Z","timestamp":1793106793410,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.eururo.2024.08.001","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T22:04:12Z","timestamp":1724537052000},"page":"516-527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Bladder-sparing Therapy for Bacillus Calmette-Gu\u00e9rin\u2013unresponsive Non\u2013muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection"],"prefix":"10.1016","volume":"86","author":[{"given":"Roger","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Hensley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikmat","family":"Al-Ahmadie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Babjuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Brausi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly K.","family":"Bree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario I.","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald L.","family":"Lamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth P.","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paramananthan","family":"Mariappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McConkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura S.","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Palou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Pohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Soloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe E.","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Svatek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Shen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikiya","family":"Taoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2024.08.001_b0005","unstructured":"Food and Drug Administration. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment. Guidance for industry. Silver Springs, MD: US FDA; 2018. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bacillus-calmette-guerin-unresponsive-nonmuscle-invasive-bladder-cancer-developing-drugs-and."},{"key":"10.1016\/j.eururo.2024.08.001_b0010","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.urology.2013.10.030","article-title":"Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop","volume":"83","author":"Jarow","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2024.08.001_b0015","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.08.001_b0020","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.08.001_b0025","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.08.001_b0030","article-title":"IL-15 superagonist NAI in BCG-unresponsive non\u2013muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.eururo.2024.08.001_b0035","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.08.001_b0040","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/BLC-170118","article-title":"Once BCG unresponsive, always BCG unresponsive: an open letter to the FDA to enhance recruitment into clinical trials in bladder cancer","volume":"3","author":"Kamat","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.eururo.2024.08.001_b0045","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1287\/mnsc.9.3.458","article-title":"An experimental application of the Delphi methods to the use of experts","volume":"9","author":"Dalkey","year":"1963","journal-title":"Manag Sci"},{"key":"10.1016\/j.eururo.2024.08.001_b0050","series-title":"EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS)","author":"Gontero","year":"2023"},{"key":"10.1016\/j.eururo.2024.08.001_b0055","series-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae). Bladder cancer. version 3.2024","author":"Network","year":"2024"},{"key":"10.1016\/j.eururo.2024.08.001_b0060","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.08.001_b0065","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2024.08.001_b0070","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/S0022-5347(05)67022-X","article-title":"The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials","volume":"164","author":"Van Der Meijden","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.08.001_b0075","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1464-410X.2009.09100.x","article-title":"Pathological stage review is indicated in primary pT1 bladder cancer","volume":"106","author":"van Rhijn","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.08.001_b0080","doi-asserted-by":"crossref","first-page":"188","DOI":"10.5489\/cuaj.4126","article-title":"Pathology review impacts clinical management of patients with T1\u2013T2 bladder cancer","volume":"11","author":"Traboulsi","year":"2017","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.eururo.2024.08.001_b0085","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/JU.0000000000002957","article-title":"Clinical and preclinical therapies for bladder cancer following bacillus Calmette-Gu\u00e9rin failure","volume":"209","author":"Nazmifar","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.08.001_b0090","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.euo.2020.02.006","article-title":"Evidence-based assessment of current and emerging bladder-sparing therapies for non\u2013muscle-invasive bladder cancer after bacillus Calmette-Guerin therapy: a systematic review and meta-analysis","volume":"3","author":"Kamat","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.08.001_b0095","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.eururo.2020.02.012","article-title":"Systematic review of the therapeutic efficacy of bladder-preserving treatments for non\u2013muscle-invasive bladder cancer following intravesical bacillus Calmette-Gu\u00e9rin","volume":"78","author":"Li","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.08.001_b0100","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1080\/14656566.2023.2271396","article-title":"Real-world efficacy of adjuvant single-agent intravesical gemcitabine for non-muscle invasive bladder cancer","volume":"24","author":"Abou Chakra","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.eururo.2024.08.001_b0105","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/14656566.2024.2310073","article-title":"Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?","volume":"25","author":"Abou Chakra","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.eururo.2024.08.001_b0110","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","article-title":"Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial","volume":"93","author":"Au","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2024.08.001_b0115","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40268-017-0183-y","article-title":"Solubilization and stability of mitomycin C solutions prepared for intravesical administration","volume":"17","author":"Myers","year":"2017","journal-title":"Drugs R D"},{"issue":"Suppl 4","key":"10.1016\/j.eururo.2024.08.001_b0120","article-title":"LBA02-03 First results from SunRISE-1 in patients with BCG unresponsive high-risk non-muscle-invasive bladder cancer receiving TAR-200 in combination with cetrelimab, TAR-200, or cetrelimab alone","volume":"209","author":"Daneshmand","year":"2023","journal-title":"J Urol"},{"issue":"5S2","key":"10.1016\/j.eururo.2024.08.001_b0125","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/01.JU.0001015816.87470.c9.01","article-title":"P2\u201301 TAR-200 in patients with bacillus Calmette-Gu\u00e9rin-unresponsive high-risk non-muscle-invasive bladder cancer: results from SUNRISE-1 study","volume":"211","author":"Necchi","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.08.001_b0130","doi-asserted-by":"crossref","first-page":"148.e1","DOI":"10.1016\/j.urolonc.2022.10.030","article-title":"Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer","volume":"41","author":"Chevuru","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2024.08.001_b0135","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/JU.0000000000000919","article-title":"A phase I trial of intravesical cabazitaxel, gemcitabine and cisplatin for the treatment of nonmuscle invasive bacillus Calmette-Gu\u00e9rin unresponsive or recurrent\/relapsing urothelial carcinoma of the bladder","volume":"204","author":"DeCastro","year":"2020","journal-title":"J Urol"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2024.08.001_b0140","article-title":"Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non\u2013muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Gu\u00e9rin (BCG): results from cohort B of the phase 2 KEYNOTE-057 trial","volume":"41","author":"Necchi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.08.001_b0145","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2023.08.004","article-title":"Phase 2 trial of atezolizumab in bacillus Calmette-Gu\u00e9rin\u2013unresponsive high-risk non\u2013muscle-invasive bladder cancer: SWOG S1605","volume":"84","author":"Black","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.08.001_b0150","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1158\/1078-0432.CCR-23-0354","article-title":"A phase II study of durvalumab for bacillus Calmette-Guerin (BCG) unresponsive urothelial carcinoma in situ of the bladder","volume":"29","author":"Li","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2024.08.001_b0155","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.euo.2023.01.013","article-title":"A phase 1b\/2 study of atezolizumab with or without bacille Calmette-Gu\u00e9rin in patients with high-risk non\u2013muscle-invasive bladder cancer","volume":"6","author":"Inman","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.08.001_b0160","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2024.08.001_b0165","unstructured":"Tyson M, Uchio E, Jong-Kil N, et al. First results from BOND-003, a phase 3 study of intravesical cretostimogene grenadenorepvec monotherapy for patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer. Presented at the 2023 Society of Urologic Oncology Annual Meeting, November 28\u2013December 1, 2023, Washington, DC. Abstract LBA3396."},{"issue":"16 Suppl","key":"10.1016\/j.eururo.2024.08.001_b0170","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1200\/JCO.2022.40.16_suppl.4597","article-title":"CORE1: phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG)","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.08.001_b0175","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1080\/14712598.2020.1738379","article-title":"Rationale for IL-15 superagonists in cancer immunotherapy","volume":"20","author":"Knudson","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.eururo.2024.08.001_b0180","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11912-022-01350-9","article-title":"Novel therapies for high-risk non-muscle invasive bladder cancer","volume":"25","author":"Al Hussein Al Awamlh","year":"2023","journal-title":"Curr Oncol Rep"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2024.08.001_b0185","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1200\/JCO.2023.41.6_suppl.512","article-title":"Clinical results of a phase 1 study of intravesical EG-70 in patients with BCG-unresponsive NMIBC","volume":"41","author":"Steinberg","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.08.001_b0190","unstructured":"Atlas SJ, Touchette DR, Beinfeld M, et al. Nadofaragene firadenovec and oportuzumab monatox for BCG-unresponsive, non-muscle invasive bladder cancer: effectiveness and value: final report. Boston, MA: Institute for Clinical and Economic Review; 2021. https:\/\/icer.org\/wp-content\/uploads\/2020\/08\/ICER_Bladder-Cancer_Final-Report_053122.pdf."},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2024.08.001_b0195","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1200\/JCO.2023.41.6_suppl.503","article-title":"Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with FGFR3\/2 alterations (alt) in THOR-2: cohort 2 interim analysis","volume":"41","author":"Catto","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.08.001_b0200","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.annonc.2023.09.3116","article-title":"Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer","volume":"35","author":"Catto","year":"2024","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2024.08.001_b0205","article-title":"LBA104 First safety and efficacy results of the TAR-210 erdafitinib intravesical delivery system in patients with non-muscle invasive bladder cancer (NMIBC) with select FGFR alteration","volume":"34","author":"Vilaseca","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.08.001_b0210","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2024.08.001_b0215","article-title":"LBA6 EV-302\/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab vs. chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma","volume":"34","author":"Powles","year":"2023","journal-title":"Ann Oncol"},{"issue":"3 Suppl","key":"10.1016\/j.eururo.2024.08.001_b0220","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1016\/j.ijrobp.2021.07.302","article-title":"NRG Oncology\/RTOG 0926: phase II protocol for patients with stage T1 bladder cancer to evaluate selective bladder preserving treatment by radiation therapy concurrent with radiosensitizing chemotherapy following a thorough transurethral surgical re-staging","volume":"111","author":"Dahl","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl 6","key":"10.1016\/j.eururo.2024.08.001_b0225","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1200\/JCO.2023.41.6_suppl.510","article-title":"Preliminary results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guerin (BCG)","volume":"41","author":"Li","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.08.001_b0230","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.eururo.2023.01.017","article-title":"A phase 1 trial of durvalumab in combination with bacillus Calmette-Guerin (BCG) or external beam radiation therapy in patients with BCG-unresponsive non\u2013muscle-invasive bladder cancer: the Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER study","volume":"83","author":"Hahn","year":"2023","journal-title":"Eur Urol"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2024.08.001_b0235","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.2023.41.6_suppl.528","article-title":"A phase II clinical study of intravesical photodynamic therapy in patients with BCG-unresponsive NMIBC (interim analysis)","volume":"41","author":"Kulkarni","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.08.001_b0240","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","article-title":"Does early cystectomy improve the survival of patients with high-risk superficial bladder tumors?","volume":"166","author":"Herr","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.08.001_b0245","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.euros.2023.04.013","article-title":"Bladder-sparing treatment in patients with bacillus Calmette-Guerin\u2013unresponsive non\u2013muscle-invasive bladder cancer: an analysis of long-term survival outcomes","volume":"53","author":"Tan","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.eururo.2024.08.001_b0250","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.08.001_b0255","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.juro.2012.10.068","article-title":"Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Gu\u00e9rin therapy","volume":"189","author":"Barlow","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.08.001_b0260","doi-asserted-by":"crossref","first-page":"35.e15","DOI":"10.1016\/j.urolonc.2013.01.009","article-title":"Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer","volume":"32","author":"Lightfoot","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2024.08.001_b0265","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/bju.13088","article-title":"Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer","volume":"117","author":"Cockerill","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.08.001_b0270","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2009.09.024","article-title":"Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort","volume":"57","author":"Fritsche","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.08.001_b0275","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.euo.2023.07.012","article-title":"Oncological outcomes for patients with European Association of Urology very high-risk non\u2013muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin or early radical cystectomy","volume":"6","author":"Contieri","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.08.001_b0280","series-title":"EAU guidelines on muscle-invasive and metastatic bladder cancer","author":"Witjes","year":"2023"},{"key":"10.1016\/j.eururo.2024.08.001_b0285","unstructured":"American Urological Association. Treatment of non-metastatic muscle invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline. Linthicum, MD: AUA; 2020. https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/bladder-cancer-non-metastatic-muscle-invasive-guideline."},{"key":"10.1016\/j.eururo.2024.08.001_b0290","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1097\/JU.0000000000001943","article-title":"Progression of Disease after bacillus Calmette-Gu\u00e9rin therapy: refining patient selection for neoadjuvant chemotherapy before radical cystectomy","volume":"206","author":"Hensley","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.08.001_b0295","doi-asserted-by":"crossref","first-page":"333","DOI":"10.48083\/CKYL2827","article-title":"Systematic review and meta-analysis of response rates in BCG-unresponsive non\u2013muscle-invasive bladder cancer: a consensus statement from the International Bladder Cancer Group","volume":"3","author":"Rose","year":"2022","journal-title":"Soc Int Urol J"},{"key":"10.1016\/j.eururo.2024.08.001_b0300","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.eururo.2021.12.009","article-title":"Antiadenovirus antibodies predict response durability to nadofaragene firadenovec therapy in BCG-unresponsive non\u2013muscle-invasive bladder cancer: secondary analysis of a phase 3 clinical trial","volume":"81","author":"Mitra","year":"2022","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824025168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824025168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T23:47:53Z","timestamp":1733874473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283824025168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0302283824025168"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2024.08.001","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bladder-sparing Therapy for Bacillus Calmette-Gu\u00e9rin\u2013unresponsive Non\u2013muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2024.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}